Ces recommandations ont été élaborées dans le cadre de la mission de l’Organisation mondiale de la Santé de fournir des orientations normatives à ses États-membres. L’objectif de ce document est de formuler des recommandations fondées sur des données factuelles afin de faciliter l’acc...ès universel aux interventions essentielles et efficaces en matière santé maternelle et néonatale, grâce à l’optimisation des rôles du personnel de santé.
Ces recommandations s’adressent aux décideurs de la santé, aux responsables et autres acteurs aux niveaux international, national et régional. En fournissant ces recommandations générales à l’échelle internationale, l’Organisation mondiale de la Santé part du principe que les pays les adapteront et qu’ils les mettront en œuvre en tenant compte du système politique et des systèmes de santé déjà en place.
more
Trouble de l'humeur
Chapitre E.3
Edition en français Traduction : Xavier Benarous
Sous la direction de : David Cohen
Avec le soutien de la SFPEADA
The meeting was held from 26 to 27 March 2018 to review and discuss the following topics:
Advances and challenges in the use of fTLC, and new approaches to detecting mycolactone using monoclonal antibodies (mAbs).
The status of development of rapid diagnostic tests (RDTs) targeting the MUL..._3720 protein.
The role of PCR as a reference test, and hurdles in providing a confirmatory diagnosis and in establishing a quality assurance programme.
New molecular tools with potential for implementation at a level lower than in the national or regional reference laboratory, such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA).
The need to harmonize and standardize methods for collection and preparation of specimens, so samples can be referred for diagnosis and stored for evaluation of new diagnostic tests in optimal conditions.
Barriers to accessing early diagnosis and treatment, including coordination at the programme level, and lack of adequate diagnostic tools.
Defining target product profiles (TPPs) to guide the development of new diagnostic tools that can be applied at different levels of the health system. Participants agreed that two TPPs would be developed to address the current gaps: (i) a rapid test for BU diagnosis at the primary health-care level; and (ii) a test for diagnosis of BU that can also assist in treatment monitoring and differential diagnosis at the district hospital or reference centre.
more
Autres troubles
Chapitre H.4
Available in Arabic, Chinese, English, French, Portuguese, Russian and Spanish
https://apps.who.int/iris/handle/10665/334254
This guidance is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention and control programme. The guidance includes a step-by-step process to be followed after the... decision has been made to specifically introduce and/or scale-up HPV virological testing for screening, which would be followed up with adequate management within the context of cervical cancer prevention
more
Public Health Action
vol 5 no 3 published 21 september 2015
Q7. SCOPING QUESTION: In adults with moderate-severe depressive disorder, what is the effectiveness and safety of antidepressant medication (ADM) in comparison with psychological treatment?
The WHO mhGAP programme’s existing guidelines recommend that either structured brief psychological treatm...ents (e.g., interpersonal psychotherapy or cognitive behavioural therapy, including behavioural activation) or antidepressant medication (e.g., SSRIsi and tricyclic antidepressants) be considered in adults with moderate-severe depression. Health care workers need to know whether these treatments have different effects, including side-effects, in treating depressive disorder in the short and long term, in order to improve clinical decision-making.
more
Autres troubles
Chapitre H.1
Edition en français
Traduction : Priscille Gérardin et Malaïka Lasfar Sous la direction de : Priscille Gérardin Avec le soutien de la SFPEADA
Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery.
The targ...et set by the World Health Organization (WHO) for control of Buruli ulcer is for countries to achieve a rate of case confirmation by PCR of at least 70%. All endemic countries have at least one PCR facility to support confirmation of cases. However, most countries in the WHO African Region have not been able to reach the target, and the rate of case confirmation has been declining
more
This document sets out the criteria and procedures to be followed by countries in verifying the interruption of yaws transmission. It is intended for use by international verification teams, national yaws eradication programmes and WHO technical staff involved in the eradication of yaws.
Guide de recommandations rapides 11 juin 2020
Depuis son identification en Chine en décembre 2019, le nouveau coronavirus responsable de la COVID‐19 s’est rapidement propagé pour causer une pandémie. Cette maladie se manifeste par des symptômes respiratoires non spécifiques de gravité var...iable et peut nécessiter une assistance respiratoire importante. Son diagnostic est actuellement confirmé grâce l’identification de l’ARN du virus grâce à un test de laboratoire utilisant la technique de la transcription inverse-amplification génique (en anglais, reverse transcriptase polymerase chain reaction, soit RT-PCR.
more
Orientations provisoires, 27 mai 2021